Axonics (Nasdaq:AXNX) announced today that it has been granted eight patents and allowed a further four applications in the past 12 months. Irvine, California-based Axonics eight granted patents and four applications to the U.S. Patent and Trademark Office relate to its portfolio of sacral neuromodulation (SNM) technology. According to a news release, the patents represent […]
Axonics Modulation Technologies
Axonics expects 40% revenue growth this year
Axonics (Nasdaq:AXNX) shares are on the rise today on second-quarter results that came in ahead of the consensus forecast amid a successful TV advertising campaign. The Irvine, California–based sacral neuromodulation technology developer posted losses of $34.1 million, or 47¢ per share, on sales of $69 million for the three months ended June 30, 2022, for […]
Axonics files FDA PMA supplement for 4th-gen rechargeable neurostimulator
Axonics (Nasdaq:AXNX) announced that it filed a premarket approval (PMA) supplement with the FDA for its next-generation neurostimulator. Irvine, California–based Axonics designed its fourth-generation rechargeable sacral neuromodulation implantable neurostimulator (INS) to reduce the frequency with which a patient needs to recharge their implanted device to just once every six months for one hour. The current […]
Axonics raises 2022 sales guidance on Street-beating Q1
Axonics Modulation Technologies (Nasdaq:AXNX) reported first-quarter financial results that topped analysts’ consensus forecast. The Irvine, California–based sacral neuromodulation technology developer posted losses of $22.7 million, or 50¢ per share, on sales of $48.4 million for the three months ended March 31, 2022, for a slight bottom-line loss of just over $150,000 year-over-year on sales growth […]
Axonics launches F15 recharge-free sacral neuromodulation system
Axonics (Nasdaq:AXNX) announced today that it launched its F15 recharge-free sacral neuromodulation (SNM) system in the U.S. Irvine, California-based Axonics received FDA approval for the F15 SNM system in March. The company designed the newly developed F15 recharge-free SNM system to feature a functional life span of over 15 years at typical stimulation parameters, with […]
FDA clears Axonics’ recharge-free sacral neuromodulation system
Axonics Modulation Technologies (Nasdaq:AXNX) announced today that it received FDA approval for its new implantable neurostimulator. Irvine, California–based Axonics designed the Axonics F15 recharge-free sacral-neuromodulation (SNM) system with a functional life span of over 15 years at typical stimulation parameters and more than 2 decades at lower-energy settings. The system’s size totals 10 cubic centimeters, […]
Axonics ticks up on Street-beating Q4, expects recharge-free SNM launch in Q2
Axonics Modulation Technologies (NSDQ:AXNX) shares rose today on fourth-quarter results that beat the consensus forecast on Wall Street. The Irvine, California-based sacral neuromodulation (SNM) technology developer posted losses of $15.2 million, or 34¢ per share, on sales of $53.1 million for the three months ended Dec. 31, 2021, for a bottom-line of nearly $4 million […]
Medtronic’s IP dispute against Axonics could resume in court after PTAB decisions
Medtronic (NYSE:MDT) and Axonics (NSDQ:AXNX) could see their patent dispute over neurostimulation technology resume in court. Yesterday, the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office affirmed an additional three patents in a long-term dispute between the companies over intellectual property for Medtronic’s Interstim sacral neuromodulation (SNM) system, completing the review process […]
Axonics loses IP challenge to Medtronic patents
Medtronic (NYSE:MDT) announced that it picked up three victories in an intellectual property (IP) dispute against Axonics (NSDQ:AXNX) over sacral neuromodulation devices. According to a news release, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected Axonics’ attempt to invalidate three Medtronic patents in its IP infringement lawsuit related to Medtronic’s […]
Axonics files FDA PMA supplement for its non-rechargeable SNM system
Axonics (NSDQ:AXNX) announced that it filed a premarket approval supplement with the FDA for its sacral neuromodulation (SNM) system. Irvine, Calif.-based Axonics filed the PMA supplement for its newly developed, long-lived, non-rechargeable SNM implantable neurostimulator (INS), according to a news release. The company designed its new non-rechargeable SNM system to replicate the key features of […]
Axonics wins CE mark approval for sacral neurostim implant
Axonics Modulation Technologies (NSDQ:AXNX) today said it received CE mark approval for its second-generation r-SNM implantable neurostimulator and wireless patient remote control. The r-SNM system is an implantable sacral neuromodulation device designed to treat urinary and bowel dysfunction. Irvine, Calif.-based Axonics previously won FDA approval for the device in April last year. Axonics’s r-SNM reduces how […]